NCT05563922View on ClinicalTrials.gov

Organ Preservation Strategy of Total Neoadjuvant Chemoradiotherapy for Low Rectal Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2027

Conditions
Rectal Cancer
Interventions
COMBINATION_PRODUCT

Total Neoadjuvant Chemoradiotherapy

"Radiotherapy：45Gy/25F+Boost 50Gy/25F. A total of 45 Gy, 25 fractions of 1.8 Gy, 5 fractions a week~CapOx:~Capecitabine 1000mg / m² po bid (1-14 days, 21 days a cycle) Oxaliplatin 130mg / m2 igtt(Day 1, 21 days a cycle) TEM or endoscopic local resection"

Trial Locations (1)

200032

RECRUITING

Fudan University Zhongshan Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER